Deferoxamine treatment for acute iron intoxication in pregnancy

Khoury, S; Odeh, Marwan; Oettinger, Moshe

doi:10.3109/00016349509021190

Cited by 16 publications

(8 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study of 25 pregnant women treated with DFO [11] and other case reports of iron intoxication [12][13][14] have also failed to show evidence of DFO toxicity to either the mother or the baby.…”

Section: Discussionmentioning

confidence: 99%

Deferoxamine treatment during pregnancy: Is it harmful?

Singer¹,

Vichinsky²

1999

Am. J. Hematol.

View full text Add to dashboard Cite

The use of the iron chelator, Deferoxamine (DFO), in pregnant thalassemia women with iron overload has been generally avoided due to fear of its potential teratogenicity. We describe a case of a pregnant thalassemia major patient with iron overload, who received DFO throughout her second and third trimesters and gave birth to a healthy infant, who had no findings of DFO toxicity at birth and at a later follow-up. Review of the literature discloses over 40 other cases in which DFO was given in various periods of gestation without evidence of teratogenic effect. Sufficient documentation exists, therefore, to suggest that DFO can be considered for use in cases of pregnant women who need iron chelation treatment. Am. J. Hematol. 60:24-26, 1999.

show abstract

Section: Discussionmentioning

confidence: 99%

Deferoxamine treatment during pregnancy: Is it harmful?

Singer¹,

Vichinsky²

1999

Am. J. Hematol.

View full text Add to dashboard Cite

show abstract

“…One pregnant woman received deferoxamine during organogenesis; her infant was normal. Several cases reports exist that describe deferoxamine use in iron poisoning in pregnant women (Tran et al, 2000); however, none occurred during organogenesis (Strom et al, 1976; Rayburn et al, 1983; Blanc et al, 1984; Olemark et al, 1987; Van Ameyde and Tenenbein, 1989; Lacoste et al, 1992; Turk et al, 1993; Khoury et al, 1995; Tran et al, 1998). Deferoxamine may also be used for the treatment of iron overload secondary to transfusion dependent beta‐thalassemia.…”

Section: Toxicological Case Series With or Without Case Reports Are Amentioning

confidence: 99%

Are there teratogenic risks associated with antidotes used in the acute management of poisoned pregnant women?

Bailey

2003

Birth Defects Research

View full text Add to dashboard Cite

Despite the limited evidence supporting the risk of antidote use during pregnancy, antidotes should be used when there is a clear maternal indication to decrease the morbidity or mortality associated with poisoning. The only exception may be penicillamine, which is a teratogen. Better antidotes exist for most poisonings that penicillamine could potentially treat. At this time, there is no known fetal indication for all antidotes. Reporting the use of an antidote during pregnancy should be encouraged, especially if used during the critical period of organogenesis.

show abstract

“…In several cases, pregnant women had signs and symptoms of iron poisoning with elevated serum iron levels, were treated with deferoxamine, and delivered healthy infants. [145][146][147][148][149][150][151] Although the placenta transports iron to the fetus efficiently, it blocks the transfer of large quantities of iron. 3 In a sheep model of iron poisoning, only a small amount of iron was transferred across the placenta despite significantly elevated serum iron levels.…”

Section: Is There a Modified Approach To Management In The Pregnant Pmentioning

confidence: 99%

“…154 In clinical case reports of iron overdose for which deferoxamine was used there have been no adverse effects on the fetus, although most have been second or third trimester poisonings. 142,[145][146][147][148][149]150,151 In 1 case series of 49 patients with iron poisoning during pregnancy, 25 women received deferoxamineJ 55 Only 1 woman who received deferoxamine in the first trimester continued her pregnancy to term; she had a healthy infant. One woman who received deferoxamine at 20 weeks had a premature delivery at 24 weeks, and another woman who received deferoxamine at 30 weeks delivered a baby at term with webbed fingers, a malformation believed to be unrelated to the intoxication or the therapy.…”

Section: Is There a Modified Approach To Management In The Pregnant Pmentioning

confidence: 99%

Iron poisoning

Fine¹

2000

Current Problems in Pediatrics

View full text Add to dashboard Cite

Deferoxamine treatment for acute iron intoxication in pregnancy

Cited by 16 publications

References 7 publications

Deferoxamine treatment during pregnancy: Is it harmful?

Deferoxamine treatment during pregnancy: Is it harmful?

Are there teratogenic risks associated with antidotes used in the acute management of poisoned pregnant women?

Iron poisoning

Contact Info

Product

Resources

About